FDA analysis: Drug prices plunge with generics competition

04/4/2006 | NYTimes.com

Competition from generics substantially reduces the prices of prescription drugs, according to an analysis by the FDA. A single challenger to a branded drug typically sells for 94% of its rival's price, but when two generics are on the market the average price drops to 52% of the name-brand's version. Prices continue to decline with even more competition, although at a slower pace, the analysis found.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations